Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Simcere Reports Slow Q1 Results, But Sales Force Reorganization Could Help Attract New Pharma Partners

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Simcere Pharmaceutical Group, one of the first Chinese domestic pharmaceutical companies to list in the U.S., reported a slow first quarter result due to slower than expected sales of lead product line first-to-market edavarone injection branded Bicun and Yidasheng.

You may also be interested in...



Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research

SHANGHAI - Although anti-infective drugs still dominate China's pharma market with roughly one-fourth of the total drug sales in hospitals, China's oncology market is outpacing the larger global market

Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research

SHANGHAI - Although anti-infective drugs still dominate China's pharma market with roughly one-fourth of the total drug sales in hospitals, China's oncology market is outpacing the larger global market

Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research

Three national surveys revealed that lung, liver, stomach and esophageal cancer were the top four killers in the last 30 years, accounting for roughly 70% of deaths from cancer in China.

Related Content

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel